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Background: Early events in HIV infection are still poorly understood; virus derived from acute infections, the
transmitted/founders IMCs, could provide more reliable information as they represent strains that established HIV
infection in vivo, and therefore are investigated to elucidate potentially shared biological features.
Methods: This study examined synergy in neutralization by six monoclonal antibodies targeting different domains
in gp120 and gp41 and assayed in pairwise combination against 11 HIV-1 clade B strains, either Env pseudoviruses
(PV, n = 5) or transmitted/founder infectious molecular clones (T/F IMCs, n = 6). Three of the early-infection env
tested as PV were juxtaposed with T/F viruses derived from the same three patients, respectively.
Results: All antibodies reaching IC50 were assayed pairwise (n = 50). T/F IMCs showed overall lower sensitivity to
neutralization by single antibodies than PV, including within the three patient-matched pairs. Remarkably, combination
index (CI) calculated using the Chow and Talalay method indicated synergy (CI < 0.9) in 42 data sets, and occurred in T/F
IMC at similar proportions (15 of 17 antibody-T/F IMC combinations tested) as in pseudoviruses (27 of 33). CI values
indicative of additivity and low-level antagonism were seen in 5 and 3 cases, respectively. Most pairs showed
comparable synergic neutralizing effects on both virus groups, with the 4E10 + PG16 pair achieving the best synergic
effects. Variability in neutralization was mostly observed on pseudovirus isolates, suggesting that factors other than virus
isolation technology, such as env conformation, epitope accessibility and antibody concentration, are likely to
affect polyclonal neutralization.
Conclusions: The findings from this study suggest that inhibitory activity of bNAbs can be further augmented
through appropriate combination, even against viruses representing circulating strains, which are likely to
exhibit a less sensitive Tier 2 neutralization phenotype. This notion has important implications for the design
and development of anti-Env bNAb-inducing vaccines and polyclonal sera for passive immunization.
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Neutralizing antibodies to HIV-1 do not generally de-
velop at early stages of infection, and thus usually cannot
inhibit HIV-1 amplification and establishment of chronic
infection. Selection pressure exerted by host immunity,
and the intrinsic ability of HIV-1 to rapidly mutate result
in great variability of HIV strains over time, and thus
virus isolates from later stages of infection can differ* Correspondence: lopalco.lucia@hsr.it
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unless otherwise stated.substantially from the early virus population and in par-
ticular from the respective transmitted virus strain(s).
Recent approaches utilizing single genome amplification
(SGA) of viral sequences from acutely infected patients
overcame prior limitations in analyzing the genomes of
viruses initiating clinical infection, thereby enabling the
identification of transmitted/founder (T/F) HIV env as
well as proviral sequences with high reliability, and the
subsequent generation of infectious molecular clones
(IMC) of T/F HIV-1 [1-3] . Biologic characterization of
T/F HIV-1 strains from different clades have begun to
reveal distinctions between T/F HIV-1 and primaryal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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adapted “reference” virus strains. T/F HIV-1 were found
to display an higher glycosylation shield, R5-mediated,
T-lymphocyte tropism and, most importantly, relative
resistance to antibody neutralization [1,4,5].
In order to develop an effective vaccine able to prevent
HIV-1 transmission, it is highly relevant to understand
the sensitivity of primary virus strains, including trans-
mitted/founder strains, to humoral defenses. Certain
commonly used laboratory-adapted strains and primary
HIV isolates are highly neutralization sensitive (“Tier 1”
neutralization phenotype) [6] and thus do not adequately
reflect the broad spectrum of neutralization observed for
primary strains from various clades. The most compre-
hensive study so far by Montefiori and colleagues [7,8],
of 219 Env-pseudotyped viruses assayed in TZM-bl cells
[7,8] with sera from 205 HIV-1-infected individuals,
highlighted this notion.
We were interested whether pair-wise combinations of
potently neutralizing monoclonal antibodies (NAbs) di-
rected against different gp120 and gp41 epitopes had
synergistic inhibitory effects against a selection of early
infection and transmitted/founder Clade B strains. We
posit that information about synergy of HIV-1 antibodies
could ultimately be exploited to select epitopes combina-
tions for immunogens that might elicit synergistic bNAbs.
We conducted our study employing the widely utilized
TZM-bl neutralization assay which was recently validated
[9]. We chose four env strains of TZM-bl Tier 2 pheno-
type cloned from early/acute infections and included in
the original Clade B env Reference Panel [10], plus one
Tier 1A control (SF162 env) for testing of pseudovirus
neutralization of a single round of infection. We juxta-
posed three of these pseudoviruses with analysis of their
matched clade B full-length transmitted/founder infec-
tious molecular clones (T/F IMCs), together with three
additional (Tier 2) clade B T/F IMCs. These bona fide
transmitted/founder genome sequences had been de-
rived from acutely infected subjects [1,2], and replication-
competent IMC representing them had been generated by
a novel strategy described previously [1,2]. Both sets of
viruses were assayed with a panel of potent human
neutralizing antibodies directed against distinct envelope
epitopes, individually and in pair-wise combination, in
order to assess whether synergistic enhancement of inhib-
ition could be achieved.
Materials and methods
Cells, monoclonal antibodies and HIV-1 viruses
The 293 T cell line (CRL-11268) was obtained from the
American Type Culture Collection (ATCC, Manassas, VA).
The TZM-bl cell line was obtained through the NIH AIDS
Research and Reference Reagent Program (NIH ARRRP),
Division of AIDS, NIAID, NIH, contributed by JohnKappes and Xiaoyun Wu [8]. The human monoclonal anti-
bodies used (mAb), 4E10, 2 F5, 2G12, b12, PG9, PG16,
were obtained from POLYMUN Scientific (Klosterneuburg,
AUSTRIA).
Clade B Env-expression plasmids for pseudovirus gener-
ation, including pREJO4551 clone 58, AC10.0 clone 29,
pCAGGS SF162 gp160 (cat #10463), pRHPA4259 clone 7,
pTHRO4156 clone18, were obtained through the NIH
AIDS Research an Reference Reagent Program. (NIH
ARRRP as part of the Clade B env pseudovirus panel).
The acute env plasmids were generated by Mascola
et al. [11] by cloning the gp160 genes from sexually ac-
quired, acute/early infections, in order to facilitate stan-
dardized assessments of neutralizing antibody responses.
When co-transfected with the env-deleted backbone plas-
mid pSG3Δenv (contributed by. John C. Kappes and
Xiaoyun Wu [12]; cat #11051, included in the Panel) in
293 T cells, these plasmids produce env-pseudotyped vi-
ruses that are capable of a single round of infection in
TZM-bl cells.
The genomic sequence of full-length transmitted/
founder (T/F) HIV-1 strains were deduced using a math-
ematical model of HIV-1 sequence evolution in acute clin-
ical infection and an experimental strategy based on single
genome amplification (SGA) of plasma vRNA/cDNA,
followed by direct sequencing of uncloned SGAs [1,4].
The derivation of bona fide T/F infectious molecular
clones (IMCs) including pCH040.c/2625, pCH058.c/2960,
pCH077.t/2627, pRHPA.c/2635, pTHRO.c/2626, pREJO.
c2864 was described previously by Ochsenbauer et al.
[2], and T/F IMC are also available through the NIH
ARRRP, contributed by John C. Kappes and Christina
Ochsenbauer.
SF162 Env has a Tier 1 A phenotype in TZM-bl PV
assay; all other strains are described as Tier 2 when
tested as Env-PV [Neutralizing Antibody Resources tools,
at www.hiv.lanl.gov].
Generation and titration of virus stocks
293 T cell-derived stocks of pseudoviruses and replication-
competent IMCs were generated by proviral DNA trans-
fection using FuGENE 6, according to the manufacturer’s
protocol (Promega, Madison, WI). Viral supernatants were
harvested 72 h post-transfection, clarified at 1800 rpm for
20 min, and frozen at −70°C. The virus stocks were further
analyzed for firefly luciferase expression in the TZM-bl cell
line. Four replicates of five-fold dilutions of virus were
added to 96 flat-bottomed plate wells containing 1 × 104
TZM-bl cells per well, in 10% D-MEM growth medium
with 7.5ug/ml of DEAE-dextran (Sigma) in a final volume
of 200ul. After 48 h incubation at 37°C, 100uL of culture
medium were removed from each well and replaced with
100 uL of Bright-Glo luciferase reagent (Promega). After
2 min incubation, 150 uL of the cell lysate was transferred
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sured using a Victor Light 2030 luminometer (Perkin
Elmer). Fifty percent infectious dose (ID50) titers were de-
fined as the reciprocal of the virus dilution yielding 50%
positive wells (Reed-Muench calculation).
TZM-bl neutralization assays
Six 3-fold serial dilutions of antibodies samples (starting
from 66ug/mL), were plated in triplicate (96-well flat bot-
tom plate) in 10% D-MEM growth medium (100 uL/well).
200 TCID50 of each pseudovirus or 20 TCID50 of each T/
F IMC were added to each well in a volume of 100 uL and
incubated for 1 h at 37°C. TZM-bl cells were then added
(1 × 104/well in a 100 uL volume) in 10% D-MEM growth
medium containing DEAE-dextran (Sigma), at a final con-
centration of 7.5 ug/mL. Assay controls included replicate
wells of TZM-bl cells alone (cell control) and TZM-bl
cells with virus (virus control). Following a 48 h incuba-
tion at 37°C, 150 uL of culture medium were removed
from each well and replaced with 100 uL of Bright-Glo lu-
ciferase reagent (Promega). After a 2-min incubation, 150
uL of the cell lysate was transferred to a 96-well black
solid plate and luminescence was measured using a Victor
Light 2030 luminometer (Perkin Elmer). The 50% inhibi-
tory dose (IC50) was calculated as the concentration of
antibody that induced a 50% reduction in relative lumines-
cence units (RLU) compared to the virus control wells,
after subtraction of cell control RLU.
Antibody combinations and synergy calculation
All antibodies that individually had achieved an IC50
against a given virus strain were combined pairwise with
each other to test for combination effects in the inhib-
ition of the respective viruses. The ratio of each antibody
concentration in the combinations was not kept con-
stant, but instead followed the dilutions scheme below:
For every mAb pair (A + B), in one column of the 96-
well plate we plated six 1:3 dilutions of a given antibody
(A), starting from one dilution above its IC50. To the
same wells we then added the other antibody (B) at a
fixed concentration corresponding to its IC50. The same
procedure was repeated reciprocally with six three-fold
dilutions of the antibody (B) to which antibody (A) was
added, plated at the constant concentration representing
its IC50. The remainder of the assay was conducted as
described above. Each experiment was repeated inde-
pendently two times.
In order to evaluate the possible synergy between the
antibodies, the inhibition data for each combination con-
dition were analyzed using the software CompuSyn [13],
which is based on a mathematic model of synergy calcula-
tion described by Chou [14,15]; Dr. Chou kindly provided
his advice on the applicability of the analysis method to
our data set and dilution layout: The “median-effectprinciple” of Chou’s method is based on a linear trans-
formation of the inhibition data. A linear function is
then fitted: log (fa/fu) = m log(D/Dm), where fa = frac-
tion affected (i.e., the normalized proportion of inhib-
ited infection); fu = fraction unaffected (i.e., 1 − fa, or
the relative residual infectivity); m is a constant deter-
mining the slope of the linear curve; Dm is the “median
effect dose”, the equivalent of the half-maximal inhibitory
concentration; and D is the concentration of inhibitor
yielding a degree of inhibition corresponding to fa.
The combination index, CI = (D(AB)A/DA) + (D(AB)B/DB)
is next calculated from the fitted values of D when inhibi-
tors A or B are used alone (DA or DB) or as constituents
of the combination (D(AB)A and D(AB)B).
Characteristic values are the following:
When CI < 0.9, the two mAbs show synergistic activity;
When 0.9 ≤CI ≤ 1.1 , the antibody pair works in
additivity:
When CI > 1.1, the two antibodies display antagonism.
As introduced above, 12 individual CI values were cal-
culated for the 2 × 6 reciprocal dilutions done for each
MAb pairwise combination. From these 12 values, aver-
age CI were obtained and the corresponding standard
deviations were also calculated.
Results
In order to assess synergistic enhancement of inhibition
by a panel of human neutralizing antibodies with differ-
ent HIV-1 envelope protein epitope specificity, the study
examined six human neutralizing mAbs, recognizing
four different env domains; 4E10 and 2 F5 antibodies
bind two contiguous epitopes within the gp41 MPER do-
main [16,17]; 2G12 antibody recognizes mannose resi-
dues located on different glycosides displayed on gp120
surface [18]; b12 antibody specifically interacts with the
CD4 binding domain on gp120 [19]; finally, PG9 and
PG16 antibodies recognize conformational epitopes on the
gp120 V1/V2 loops, binding to various, non-contiguous
mannose residues of the glycosidic moiety [20-22].
All monoclonal antibodies were assayed in the TZM-bl
neutralization assay [9] against a virus panel including five
Clade B pseudoviruses and six infectious molecular clones
(IMC), representing Clade B Transmitted/Founder HIV-1
strains [2]. In three cases, both pseudoviruses acute /early
env strains and T/F IMC were derived from the same pa-
tient; Table 1 summarizes relevant features of monoclonal
antibodies and viruses used in the study.
Single antibody neutralization assays
Prior to conducting combinatorial inhibition assays, all
antibodies were first assayed in individual neutralization
assays against each virus in the panel, in order to assess
Table 1 Summary of antibodies and virus strains used in the study.







B. env strains used for Pseudovirus Clade Subject identifier Accession Number Gender Mode of Transmission Fiebig Stageb
SF162 B N.A. EU123924 Male N/A VI
AC10.0.29 B AC10.0 AY835446 Male MSMa III
REJO4541.67 B REJO4541 AY835449 Male HSX II
RHPA4259.7 B RHPA4256 AY835447 Female HSX ≤ V
THRO4156.18 B THRO4156 AY835448 Male MSM II
C. IMC of T/F strains
CH040.c B 700010040 JN944939 Male MSM T/F IMCc
CH058.c B 700010058 JN944940 Male MSM T/F IMCc
CH077.t B 700010077 JN944941 Male MSM T/F IMCc
REJO.c B REJO4541 JN944943 Male HSX T/F IMCc
RHPA.c B RHPA4256 JN944944 Female HSX T/F IMCc
THRO.c B THRO4156 JN944947 Male MSM T/F IMCc
A. Monoclonal antibodies used and respective target epitope on Env; * on gp41 and † on gp120
B-C. Virus used: Pseudovirus (B) and Transmitted/Founders (T/F) IMCs (C).
aMSM, men who have sex with men; HSX, heterosexual.
bThe stage of HIV-1 infection, as defined by Fiebig et al. [15], at which samples were obtained.
cT/F IMCs represent the genomes of the strains that initiated clinical infection in the respective subjects. For detailed description, see C. Ochsenbauer et al., [2].
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each PV and IMC HIV strain. As shown in Figure 1, only
b12 achieved 50% neutralization in 10 out of 11 viruses,
( 5/5 pseudoviruses and 5/6 T/F IMC). The Nabs 2 F5
and 4E10 neutralized 7 and 8 viruses, respectively, both
neutralized 3/6 T/F IMC, and 4/5 and 5/5 pseudo-
viruses, respectively, while other antibodies achieved
50% neutralization in a lower number of isolates. The
2G12 antibody only achieved 50% inhibition in 1/5 and
1/6 virus isolates, respectively.
For the three patient-matched pairs (REJO, THRO and
RHPA), T/F IMCs generally showed lower sensitivity to
neutralization than pseudoviruses with acute/early envs
from the same patients, respectively. Among the matched
virus pairs, PG16 antibody only neutralized REJO and
RHPA but sensitivity to neutralization of the PV and
patient-matched T/F IMC was very similar, with IC50
values of comparable magnitude (within 1.5-fold to 2.2-fold
range). However, some antibodies failed in 50% neutralizing
the T/F IMC counterparts of the tested PV (e.g. b12 against
REJO.c, and 2 F5 against RHPA.c; Figure 1), or the corre-
sponding IC50 value for T/F IMC was by far higher (e.g. >7-
fold for 4E10 and b12 against THRO.c; Figure 1). These
findings are intriguing, however, investigation of the under-
lying mechanism was outside of the scope and purpose ofthis study. Representative neutralization curves obtained
for pseudoviruses (panels A-B-C) and T/F IMCs (panels
D-E-F) from the same subjects (REJO, RHPA and THRO)
are shown in Figure 2; neutralization curves were smooth
and fulfilled standardized assay acceptance criteria.
Paired neutralization assays
Once we had assessed neutralization activity of individ-
ual antibodies against each virus strains, those antibodies
which reached IC50 against a respective virus strain, and
thus demonstrated potency, were assayed in pairwise
combination against this strain, in order to test for po-
tential synergistic or antagonistic activity. Each anti-
body pair was tested using reciprocal dilution schemes:
the concentration of one antibody was kept constant at
its IC50 concentration, while the second antibody was
used at 6 three-fold dilutions, starting at one dilution
above the IC50, and vice versa. This dilution scheme is
a valid method to quantify the so-called Combination
Index (CI) as a measure of synergistic, additive or an-
tagonistic effects, utilizing the Chow and Talalay equation
illustrated in Material and Methods [14,15]. Compared to
the more commonly known matrix-style dilution approach,
our approach offers the advantage of utilizing significantly
less MAb and assay reagents while generating similarly
Figure 1 Heat map of the IC50 values obtained with the antibodies tested individually against all virus strains. The x axis of the color
key represents the IC50 range in logarithmic scale. Darker cells (blue and green) indicate lower IC50 values and potent neutralization. Lighter cells
indicate no detectable or relatively weak neutralization. The non-trasformed IC50 values are indicate in each field and are expressed in ug/mL.
The names of T/F IMCs are provided. Pseudoviruses (PV) are indicated by the respective env clone identifier.
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pairs can range from synergy (CI < 0.9), to additivity (CI
ranging 0.9-1.1) and antagonism (CI > 1.1) [14,15].
In all cases in which antibody combinations were tested
against PV (n = 33) and T/F IMC (n = 17), at least 50% in-
hibition of infection were observed (data not show). Figure 3
illustrates examples of neutralization curves obtained for
three antibody pairs tested against REJO PV which resulted
in CI values indicative of synergistic, additive and antagon-
istic effects, respectively.
The 12 individual CI values generated for each mAb
combination against each tested virus strain are illus-
trated in Figures 4 and 5, and Table 2 summarizes mean
CI values and standard deviations for all antibody com-
binations (n = 50), observed against pseudovirus and T/F
IMC strains. CI values indicative of synergy (CI < 0.9)
were observed in 42 data sets. Of those, 11 synergisticdata sets (n = 8 in PV group, n = 3 in T/F IMC group;
data obtained from nine different antibody combina-
tions) with mean CI <0.9 had standard deviations that
reached into the range of additivity; in Table 2 they are
indicated with hatched light grey shading to distinguish
them from the 5 data set for which CI values indicating
additivity were obtained (medium grey shading). CI values
indicative of low-level antagonism were seen in 3 cases
(dark grey shading).
Antibody combination including either 4E10 or 2F5,
with the exception of [4E10 + 2F5], displayed synergis-
tic neutralization of all (4E10: 15/15) or most (2F5: 13/15)
tested pseudoviruses and T/F IMC. Combinations of
2F5 antibody with b12 or PG16 resulted in synergistic
neutralization of 5 out of 6 (with the sixth one showing
borderline additivity), and 4 out of 4 tested virus strains,
respectively (Table 2). For T/F IMCs, which had shown
Figure 2 Representative example of neutralization curves obtained on TZM-bl cells, using the antibodies listed in Table 1.
Pseudoviruses with the three indicated envelope glycoproteins (A,B,C) were compared to T/F IMCs (D,E,F) derived from the same subjects.
Values correspond to mean of three different experiments. Curves for tested antibodies that did not reached 50% of virus neutralization at the
highest concentration used (66.67ug/mL) are omitted for clarity.
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than pseudoviruses, fewer Ab combinations were thus tested
(n = 17) than for pseudoviruses (n = 33). Nevertheless, the
majority of T/F IMC (15/17) were neutralized synergistically
by the tested Ab combinations; the two exceptions occurred
for REJO.c (Table 2 and Figure 4, blue triangles). As illus-
trated in Figure 4, the mean of all individual CI values ob-
tained with a given Ab combination fell into the synergy
range for 11/12 Ab combinations tested against T/F IMC,
and for 11/13 Ab combinations tested against PV. This
finding suggest that IMCs were no less susceptible than
pseudoviruses to synergistic activity of antibodies which
individually neutralized at least 50%.
Most antibody pairs worked in synergy against all strains
they were tested for. However, additivity as well as antag-
onism were observed for neutralization of both REJO PVFigure 3 Representative example of synergy (A), additivity (B) and an
combining 2 antibodies in a non-constant ratio against the PV REJO4541.67and T/F IMC, for SF162 PV, and for AC10.0 PV (border-
line additivity for 2F5 + b12), (Table 2). From a functional
point of view, four pairs of antibodies targeting different
domains displayed synergic activity against both pseudo-
viruses and T/F IMCs (4E10 + b12, 4E10 + PG9, 4E10 +
PG16, 2F5 + PG16). Interestingly, as illustrated in Figure 4,
all individual CI values, and not only their respective
means, derived for the 4E10 + PG16 combination fell
in the range of synergic inhibition of all tested strains
(3 PV, 1 T/F IMC). This was also the case for b12 +
PG16 against the same three PV strains (Figure 4, cir-
cles). In contrast, for other antibody combinations tested
against PV, or both PV and T/F IMC, not all 12 CI values
for a given virus fell within “synergy” range, despite their
respective mean CI indicating synergy, e.g. CH077.t T/F
IMC (orange triangles) with [b12 + PG16] and REJO4551tagonism (C). Neutralization curves and respective CI obtained
. Nt %: percentage of viral neutralization.
Figure 4 Scatter plot showing Combination Index (CI) values for the indicated two-NAb combinations against P, Pseudoviruses; T/F,
Transmitted/Founder IMCs. Bars represent mean of all CI in each category (PV; T/F IMC). Each point represents the CI obtained for one of the
12 different dilutions of the two antibodies in the respective antibody combination (See Material and Methods for details). Circles and triangles
represent PV and T/F IMC, respectively; each color corresponds to each single virus: Purple, SF162, Red, AC10, Blue, REJO, Green, RHPA, Pink,
THRO, Brown, CH040; Dark Yellow, CH058 and Orange, CH077.
Figure 5 Scatter plot with Mean and Standard deviation of all individual CI values from all combinations antibody combinations tested
against Pseudoviruses (P) and T/F IMCs. The p-value was calculated with the two-tailed Wilcoxon test.
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Table 2 Mean and Standard deviation of the Combination Indexes (CI) of antibody pairs assayed against PV and T/F IMC, respectively
PSEUDOVIRUS T/F IMC Average
Combination index
SF162 AC10. 0.29 REJO 4551.67 RHPA 4259.7 THRO 4156.18 REJO.c RHPA.c THRO.c CH040.c CH058.c CH077.t Pseudo T/F
4E10 + 2F5 1.87* ± 0.59 0.79*** ± 0.17 1.12** ± 0.29 0.38 ± 0.11 - 1.76* ± 0.44 - - 0.41 ± 0.3 - - 1.04 1.08
4E10 + b12 0.32 ± 0.18 0.84*** ± 0.21 0.64 ± 0.13 0.18 ± 0.07 0.87*** ± 0.21 - - 0.6 ± 0.17 0.016 ± 0.018 - - 0.57 0.3
4E10 + 2G12 0.6 ± 0.25 - - - - - - - - - - 0.6 n.d.
4E10 + PG9 - 0.455 ± 0.16 0.85*** ± 0.15 - - 0.41 ± 0.07 - - - - - 0.65 0.41
4E10 + PG16 - 0.25 ± 0.14 0.61 ± 0.16 0.2 ± 0.07 - 0.35 ± 0.17 - - - - - 0.35 0.35
2F5 + b12 0.68*** ± 0.37 0.91** ± 0.19 0.58 ± 0.13 0.27 ± 0.09 - - - - 0.36 ± 0.16 0.43 ± 0.15 - 0.61 0.39
2F5 + 2G12 0.82*** ± 0.49 - - - - - - - - 0.31 ± 0.19 - 0.82 0.31
2F5 + PG9 - 0.54 ± 0.13 0.91** ± 0.2 - - 0.66 ± 0.16 - - - - - 0.72 0.66
2F5 + PG16 - 0.22 ± 0.05 0.78*** ± 0.23 0.34 ± 0.09 - 0.38 ± 0.1 - - - - - 0.44 0.38
b12 + 2G12 0.72*** ± 0.72 - - - - - - - - 0.48 ± 0.14 - 0.72 0.48
b12 + PG9 - 0.68 ± 0.2 1.02** ± 0.39 - - - - - - - 0.48 ± 0.14 0.85 0.48
b12 + PG16 - 0.29 ± 0.21 0.72 ± 0.09 0.31 ± 0.17 - - 0.8*** ± 0.18 - - - 0.61*** ± 0.32 0.44 0.66
2G12 + PG9 - - - - - - - - - - - n.d n.d
2G12 + PG16 - - - - - - - - - - - n.d n.d
PG9 + PG16 - 0.38 ± 0.11 2.92* ± 0.54 - - 0.93** ± 0.18 - - - - 0.72*** ± 0.36 1.65 0.82
*indicates CI values that indicate antagonism (n=3).
**indicates CI values that fall in the range of additivity (n=5).
***indicates CI values that, due to the range of their standard deviations, fall into additivity and synergy (n=8).
All remaining CI values fall only in the range of synergy (n = 34).
Average CI of both group combinations are indicated in Italic.
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AC10.0 pseudovirus (red circles) with 2F5 + b12, and
REJO PV (blue circles) with 4E10 + 2 F15 are examples of
a few additional virus/Ab combinations that resulted in a
wide range of CI values, and for which the mean CI did
not indicate synergy.
Of note, combinations of antibodies recognizing the
same overall domain or adjacent epitopes, such as PG9 +
PG16 on gp120 or 4E10 + 2F5 on gp41, resulted in CI
values ranging from synergy to antagonism, depending on
virus strain (Figures 3, 4 and Table 2).
Discussion
In natural infection, broadly neutralizing antibodies (bNAbs)
are generated too late to halt early infection events, and the
effectiveness of humoral immunity is further hampered by
virus escape in response to developing immune pressure.
However, the generation of bNAbs via preventive vaccin-
ation could possibly block HIV acquisition. Thus, much
effort is being placed on defining optimal immunogens
to elicit effective bNAb responses. As the number of
identified T/F env genes continues to grow, a detailed
understanding of whether T/F strains may share ―
within or across clades ― certain global features affecting
neutralization sensitivity will underpin discovery of suit-
able neutralization targets and, thus, development of a
preventive vaccine inducing effective virus neutralization.
The question whether combination of broadly reactive
antibodies directed against distinct epitopes may have syn-
ergistic, additive or antagonistic effects on neutralization
potency has not been adequately addressed. Thus, in
this study, a limited scope assessment of such effects
on the neutralization of five Env-pseudotyped viruses
and six T/F ICMs by six human broadly neutralizing
antibodies was performed. All but one of the HIV-1
strains have been ascribed a Tier 2 neutralization
phenotype in TZM-bl/PV assays; only SF162 possesses a
Tier 1A phenotype (Neutralizing Antibody Resources
Tools, at www.hiv.lanl.gov) [23]). To our knowledge,
this is the first study to test human bNAbs individually
and in pair-wise combinations against a panel of clade
B T/F viruses; among them, three T/F virus strains,
REJO.c, RHPA.c and THRO.c, were juxtaposed with
pseudoviruses with early infection env genes derived
from the same patients, respectively.
Interestingly, the three pseudoviruses and T/F IMCs
sharing the nearly identical env sequence, i.e. REJO, RHPA
and THRO (with two, two, and one amino acid differ-
ences, respectively, between early infection and T/F envs;
Additional file 1: Figure S1), displayed overall similar pat-
terns of neutralization by single antibodies, however, IC50
values for IMC were generally higher, or not reached
(i.e. IC50 > 66 μg/ml) (Figure 1). For example, the Env
proteins in REJO PV and IMC have no substitutionsand a shared insertion (Ile) in the b12 epitope, but differ
from one another in aa 255 (Ala vs. Val), 2 positions up-
stream of Ser257-Thr258 residues which are part of the b12
epitope (Additional file 1: Figure S1); this variation may
contribute to the very different IC50s observed for these
viruses (2.58 ug/mL vs >66 ug/mL). Similarly, Env proteins
in RHPA PV and IMC differ from one another immedi-
ately following the LTRGD437 portion of the epitope, and
resulted in different IC50 values (0.15 vs 1.08 ug/mL).
However, Env in THRO PV and IMC were identical to
one another in and around the b12 epitope but still dis-
played different IC50 (0.83 vs 12.87 ug/mL, respectively).
Thus, Env sequence alone cannot fully explain the sensi-
tivity of a specific viruses to a given antibody, nor differ-
ences between pseudoviruses and IMCs sharing the same
or highly similar env sequence. Of note, previous studies
also reported different sensitivity (IC50) of IMC and
pseudoviruses with identical env genes to single anti-
body neutralization, regardless of virus clade [24,25].
In both reports, the pseudoviruses were found to be
less sensitive than IMCs to specific mAb neutralization
[24,25]. However, because of small sample numbers in
each study it cannot be ruled out that these results are
env-strain specific rather than PV versus IMC specific.
In our study including early-infection env PV and T/F
IMC, the IMCs generally showed higher IC50 values in
single NAb neutralization assays (Figure 1). However,
importantly, antibody pair synergy was observed at a
higher proportion in IMC than in pseudovirus assays
(Figure 4), suggesting that IMCs were as susceptible
to synergistic antibody activity as pseudoviruses. Moreover,
substantial similarity between IMCs and PV emerged when
the distribution of all individual CI values within each
group was compared (Figure 5), and no significant differ-
ences between IMCs and PV were documented.
Differences in neutralization sensitivity between IMCs
and PV could be due to the two genetically distinct pro-
viral backgrounds since IMCs encompass a complete au-
tologous viral genome from which env is expressed in cis
under the control of the autologous LTR [2,4]. In con-
trast, pseudoviruses are derived by complementing a
common env-defective backbone with heterologous env
genes expressed in trans [2,4]. Not surprisingly, other
studies have reported that different ratios of backbone and
env-plasmids transfected in host cells were found to give
rise to pseudovirus particles endowed with different enve-
lope features, such as the proportion of env protein cleav-
age and the level of gp120 surface expression [26]; such
changes in envelope features were found to affect pseudo-
viruses infectivity, and, possibly, antibody reactivity [26].
Indeed, host cells are known to impact biochemical and
structural features of virus particles, e.g. in terms of pro-
tein processing, folding and glycosylation patterns [25].
Viruses cultured in PBMC or in primary cells were found
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obtained from laboratory-adapted cell lines, for example
due to a different glycosylation pattern shielding key epi-
topes and preventing antibody neutralization [24]. How-
ever, previous studies investigating structural changes
among virus structure or protein composition, failed to as-
sociate differences observed in IC50 values or infectivity
with any well-defined structural or biochemical feature
[26]. In our study, both pseudoviruses and T/F IMCs were
produced in 293 T cells, therefore diversity in antibody
sensitivity cannot be ascribed here solely to the effect of
host cells. We also strove to minimize other possible
sources of variability in neutralization result by choosing a
standardized, validated method, the TZM-bl assay [9], to
perform all assays. Prior to standardization, unsatisfactory
assay equivalency among laboratories had been observed
even when reagent batches were shared [27].
As was expected, no single antibody neutralized all
virus isolates, neither in the pseudovirus nor the T/F
IMC group (Figure 1). The b12 antibody, targeting a
conserved epitope within the CD4 binding site, achieved
50% neutralization on most T/F strains (5/6), and all PV
strains (5/5). The 2G12 antibody was poorly reactive
against 9 out of 11 viruses, neutralizing only SF162 pseu-
dovirus and CH058 T/F IMC; this finding is in concord-
ance with the absence of critical amino acid residues
(N295, N332, S334, N339) of the 2G12 epitope, and gly-
cosylation, in the resistant strains, respectively. PG16
was more reactive than PG9, neutralizing nearly half of
virus strains in both panels (Figure 1). Sensitive virus
strains in the study do share N156 and N160 glycosylation
sites, which are crucial for PG9/PG16 binding (Additional
file 1: Figure S1). Conversely, SF162 PV Env, and CH058.c
and CH040.c IMC, lacking N160, showed resistance to
these mAbs (Figures 1 and 2). THRO PV and IMC
were resistant to PG9/PG16 mAbs, albeit the presence
of both N156 and N160 glycosylation sites, possibly
due to a K178R mutation in the epitope (Additional
file 1: Figure S1).
MPER antibodies 4E10 and 2F5 each neutralized 3/6 T/F
IMC, and 5/5 (4E10) and 4/5 (2F5) PV, respectively
(Figure 2). Of note, IC50 values for both bNAbs dif-
fered seven- to ten-fold between patient-matched Env
proteins expressed in either the PV or IMC context
(IC50 values higher or not reached in IMC) despite
identical MPER sequence. The MPER domain in gp41
is usually weakly recognized by neutralizing antibodies
in native virus particles [28,29]. Since 2F5 and 4E10
mostly recognize MPER epitopes when gp41 is con-
formed in pre-hairpin intermediate [28-30], the higher
IC50 values obtained against T/F REJO, RHPA and THRO
strains may be explained by a more compact and stable
conformation of Env expressed in cis from T/F IMCs
as compared to their respective pseudovirus counterparts[31], a feature that could increase binding restriction and
result in poor accessibility to antibodies [32].
Since humoral responses to pathogens are usually
polyclonal, synergy and antagonism between antibodies
may naturally occur. Due to their dimensions, neutraliz-
ing antibodies do not cluster on one unique Env mol-
ecule within the trimer, but are likely to bind distinct
monomers within a single ― or within two proximal ―
trimer spikes [30,33]. Electron microscopy and mathem-
atical modeling have not yet determined the spike num-
ber required to carry out infection successfully, however,
HIV particles are studded with only a low number of
spikes (between 4–45), sparsely distributed on the enve-
lope membrane [34]. Therefore, synergy and antagonism
would result from the interaction of two or more anti-
bodies with a population of molecular targets, where
each single virus particle can carry a number of trimer
spikes as well as Env dimers or monomers [33-35], and
it cannot be readily assumed that two antibodies would
have synergistic or antagonistic effects because they were
bound to the same Env molecule. Due to the inherit
variability of the envelope protein, a relevant question is
whether in the in vivo context the presence of prolonged
Nabs activity may play a role in modulating evolution of
the disease. Although it is worth mentioning that Nabs
have been associated with control of the disease in
Long-Term Non-Progressor subjects, where an equilib-
rium has been established between virus and host, we
cannot exclude that over time mutations occurring
within the envelope can affect neutralizing activity thus
resulting in an antagonism rather then synergy. This
latter situation could occur when the patients’ clinical
status changes to rapid progressors, thus loosing the
previously established equilibrium. In this regard, the
different density level of envelope spike could play a
crucial role as well. The low density of envelope spikes,
a distinguishing feature when compared with viruses
to which protective neutralizing antibody responses
are consistently raised, directly impedes bivalent bind-
ing by IgG antibodies. The result is a minimization of
avidity, normally used by antibodies to achieve high affin-
ity binding and potent neutralization, thereby expanding
the range of mutations that allow HIV to evade antibodies.
Understanding limitations to avidity may be essential to
establish whether specific antibodies combination can dif-
ferentially modulate their activity, in particular upon vari-
ability on the density of envelope spike during the course
of chronic infection.
Not all antibody combinations were tested against all
PV and T/F IMC strains since not every antibody had
reached IC50 individually. In all cases in which antibody
combinations were assayed (n = 33 for PV; n = 17 for
T/F IMC), inhibition levels of at least 50% were reached.
Remarkably, synergy was observed in 42 out of 50 assays.
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with T/F ICMs; four with pseudovirus assays). Low level
antagonism was observed in three assays (one with T/F
IMC, two with PV, respectively) and involved antibody
combinations 2F5 + 4E10, and PG9 + PG16 which target
related epitopes (Figures 2, 3, 4, Table 2). Nearly all anti-
body pairs achieved synergistic inhibition of both pseudo-
viruses and T/F IMCs, respectively, with a few and
possibly virus-strain specific exceptions (Table 2). Findings
from the bNAb pair assays, thus, suggest that synergy
usually occurs when antibodies targeting different env
domains were involved (e.g. 4E10 ― or 2F5 ― with
b12 or with PG16). In other words, association of two
suitable antibodies could induce a favourable conform-
ational change, when binding the same monomer in a tri-
mer or even when binding different monomers, therefore
creating favourable conditions for synergic activity. From
this point of view, synergy between b12 and MPER-
targeting antibodies is not surprising, because CD4
binding takes usually place before gp41 exposure and
promotes Env refolding into the intermediate, extended
conformation [29,36]. Similarly, b12 binding could en-
hance accessibility of 4E10 (or 2F5) antibodies to MPER
domain by inducing suitable conformational changes in-
volving both gp120 and gp41 glycoproteins [30,37,38].
Combinations of PG9 + PG16 and the 2F5 + 4E10 anti-
bodies, with members of each pair targeting overlapping
or adjacent epitopes, were tested as controls. Surpris-
ingly, their mean CI values ranged from synergy to an-
tagonism depending on virus isolates (Table 2). In some
cases all 12 individual CI values for each bNAb pair/
virus combination (Figure 4) fell into only one category
(e.g. for 4E10 + 2F5 vs RHPA PV), while in others the in-
dividual CI values differed over a wide range depending
on NAb concentrations (e.g. synergy for 4E10 + 2F5 ver-
sus REJO PV). While antagonism observed with the
PG9 + PG16 pair may be explained by steric hindrance
or target competition, since both of them bind V1-V2
loops of gp120 or quaternary structures exposed on the
top of the gp120 trimer [39,40], it is noteworthy that an-
tagonism was seen in only one out of four tested virus
strains. The PG9/PG16 binding site determinants on
gp120, and Env trimers, are not fully resolved; the N160
glycosylation site, shared by most HIV isolates, is one
unique feature precisely attributed to both binding sites, and
its mutations are known to affect PG9-PG16 neutralization
[41]. All viruses tested in the study share N160 glycosylation
site within their gp120 sequences (see Additional file 1:
Figure S1), however they differ in the amino acid posi-
tions in the adjacent contact sites and displayed different
neutralization sensitivity to PG9 and PG16, possibly be-
cause not all gp120 molecules and Env trimers could
effectively bind PG16 and PG9. In the case where PG9
and PG16 neutralize individually, but their activity isantagonistically affected in combination it is possible
that the PG9 and PG16 pair compete for the same
binding site when both present, and thus causing an-
tagonism [34] .
The 2F5 and 4E10 antibodies recognize two contigu-
ous, linear epitopes along MPER, which are especially ―
but not exclusively ― accessible in pre-fusion gp41, i.e. the
pre-hairpin intermediate. Differently from PG9-PG16, the
two MPER epitopes are close, but not overlapping; more-
over, 2F5 and 4E10 antibodies target epitopes which are
made accessible on different conformations of gp41 [36]
therefore, their binding may not be competitive under
some conditions [42], and in an Env strain dependent
manner. Due to the nature of the epitope conformation
and to MPER refolding, the 4E10 epitope may be accessible
on native gp41 and throughout gp41 refolding, while the
2F5 epitope is accessible only during early phases of hair-
pin formation [36]. In addition, mutations involving the
CDR-H3 region in 2F5 and 4E10 are known to reduce their
interaction with lipids without altering epitope binding, but
make these antibodies non-neutralizing [28]. The notion of
the better and more prolonged accessibility of the 4E10 epi-
tope versus the 2F5 epitope was supported by studies in
which 4E10 showed a broader neutralizing activity than 2F5.
Due to misfolding, symmetry within Env trimers may
be disturbed, making MPER epitopes ― as well as any
other Env epitope ― more easily accessible to antibodies
[43]. Furthermore, 2F5 antibodies representing different
isotypes (IgA2 and IgG1) displayed synergic neutralizing
activity even though they were directed against the same
2F5 epitope , probably by accessing and blocking 2F5
epitopes on distinct gp41 molecules within or between tri-
mers [44]. Hence, the 4E10-2F5 range of synergy-additivity-
antagonism observed in the study may result from binding
to individual monomers in single or multiple trimers as well
as from strong membrane interactions, with unexpected ef-
fects on virus infectivity [12,17,28,36,45-47].
In future work it will be of interest to explore whether
antibodies that individually are poorly inhibitory and fail
to reach IC50 could nevertheless be more potent in
combination, due to synergic effects. To further validate
the findings from our study that bNAb synergy may be a
rather ubiquitous occurrence and thus may be harnessed
to inhibit HIV-1 infection, it would be ideal to test a lar-
ger panel of circulating HIV-1 strains against additional
bNAbs from the ever-growing reservoir. The recently
described multi-clade Global Panel of 12 Env clones
from the Neutralization Serotype Discovery Project (NSDP)
was shown to represent the continuum of neutralization
phenotypes observed for globally circulating HIV-1 strains
[7]. Thus, testing for bNAb synergy against the Env Global
Panel would be highly relevant and timely to gain a deeper
understanding of the prevalence and potential of synergic
effects on neutralization.
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ing synergic antibody responses have the potential to
augment inhibition of transmission and early virus infec-
tion, provided that polyclonal responses are employed
and that their synergic potential can be fully exploited.
Although many open questions remain regarding bNAb
synergy, exploiting synergy between more easily inducible
individual broadly neutralizing antibodies with more
limited potency holds promise for effective vaccination
strategies.Conclusion
IMCs of HIV-1 strains which have established clinical
infection in vivo afford the opportunity to elucidate rele-
vant biological features of transmitted/founder HIV-1. So
far, vaccine approaches have failed to elicit the most potent
broadly neutralizing antibodies (bNAbs). In this study, we
investigated whether pairwise combination of six bNAbs
may result in synergic effects on the neutralization of six
T/F IMC strains, and pseudoviruses with five env strains,
thus augmenting inhibitory potential of individual bNAbs.
Three of the early-infection envs tested as PV were juxta-
posed with T/F viruses derived from the same three pa-
tients, respectively.
Albeit we observed generally higher resistance of T/F
IMCs to neutralization as compared to the tested pseudo-
viruses, a similar degree of synergistic activity of antibody
pairs was achieved with both virus groups, irrespective of
the presentation of Env on virions following expression in
cis or in trans. Immune strategies eliciting antibody re-
sponses with epitope specificities that favor synergic
activity, thus, hold promise to improve inhibition of
transmitted/founder and early infection virus strains.
Not unexpectedly, we observed that the nature of epi-
topes targeted by Nabs in paired assays affected the
synergic versus additive or antagonistic effects. In our
limited-scope study, the 4E10 and PG16 antibodies,
when paired, showed optimal synergic activity on both
T/F IMC and early-infection env PV HIV-1.
The results from this study suggest that considering
the concept of synergy between more easily inducible in-
dividual broadly neutralizing antibodies which may have
more limited individual potency may be useful for de-
signing vaccines and passive immunization approaches.Additional file
Additional file 1: Gp160 amino acid sequence alignments of env
genes used for pseudotyping and from Transmitted/Founder
viruses derived from the same subjects, A) REJO4541, B) RHPA4259,
C) THRO4156, respectively.
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